Jian Sun
About Jian Sun
Jian Sun is a Senior Researcher Investigator at BeiGene specializing in structure-based drug discovery for cancer treatment.
Education and Expertise
Jian Sun completed his undergraduate studies in Physics at East China Normal University, earning a Bachelor's degree from 2003 to 2007. He then pursued a Doctor of Philosophy (PhD) in Biochemistry and Molecular Biology at the University of Chinese Academy of Sciences, completing his doctorate between 2007 and 2013. Jian Sun specializes in structure-based drug discovery, with a particular focus on cancer treatment, blending his strong background in biochemistry, molecular biology, and physics.
Current Role at BeiGene
Jian Sun has been serving as a Senior Researcher Investigator at BeiGene since August 2019. In this role, he contributes to advanced research projects in the pharmaceutical industry, leveraging his extensive knowledge in structure-based drug discovery aimed at developing cancer treatments. His work at BeiGene focuses on translating his academic research experience into practical applications within the biotechnology sector.
Past Experience at Nanyang Technological University
Jian Sun was a Senior Research Fellow at Nanyang Technological University (NTU) for 11 months from 2018 to 2019. Earlier, he held the position of Postdoctoral Research Fellow at NTU from 2014 to 2015 for one year. During his tenure at NTU, Jian Sun was involved in various advanced research projects, applying his expertise in biochemistry and molecular biology.
Research at Penn State University
From 2015 to 2018, Jian Sun worked as a Postdoctoral Research Fellow at Penn State University for three years. His research at Penn State was centered around advanced biochemical studies, contributing significant findings in the field of molecular biology. This experience further solidified his expertise in academic research before transitioning to the pharmaceutical industry.
Experience in Academic and Industrial Research
Jian Sun has extensive experience in both academic and industrial research settings. His academic career includes significant positions at renowned institutions such as Nanyang Technological University and Penn State University. These roles involved him in cutting-edge research projects focused on biochemistry and molecular biology. In August 2019, he transitioned to BeiGene, where he now leverages his academic background to contribute to the development of innovative cancer treatments in the biotechnology industry.